67752-27-6

Usage

Uses

Used in Pharmaceutical Industry:
3-(3'-Quinolinyl)acrylic acid is used as a key intermediate for the synthesis of various pharmacological compounds due to its potential medicinal properties. Its unique molecular structure allows it to be incorporated into the development of new drugs with specific therapeutic effects.
Used in Drug Development:
3-(3'-Quinolinyl)acrylic acid is used as a building block in the design and synthesis of novel drug molecules. Its presence in the molecular structure can contribute to the drug's pharmacological activity, making it a valuable component in the creation of new therapeutic agents.
Used in Medicinal Chemistry Research:
3-(3'-Quinolinyl)acrylic acid is used as a research tool in medicinal chemistry to explore its potential as a therapeutic agent. Its unique properties and interactions with biological targets can provide insights into the development of new drugs and treatment strategies.

Upstream product

• 13669-42-6 3-quinolylcarboxaldehyde 
• 141-82-2 malonic acid 
• 5332-24-1 3-bromoquinoline 
• 140-88-5 ethyl acrylate 
• 477250-21-8 3-quinolineacrylic acid methyl ester 

Downstream Products

• 1321992-27-1 C₁₉H₂₄N₂O 
• 1321992-28-2 C₁₉H₂₄N₂O 
• 1321991-90-5 3-(2-aminoquinolin-3-yl)-N-cyclohexyl-N-methylpropanamide 
• 478039-34-8 N-cyclohexyl-N-methyl-3-(quinolin-3-yl)acrylamide 
• 1321991-95-0 3-(2-aminoquinolin-3-yl)-N-(cyclohexylmethyl)propanamide 

Relevant academic research and scientific papers

Cis-cinnamic acid analogue, gravitropism modifier (by machine translation)

[Problem] cinnamic acid or cinnamic acid analogue comprising adjusting agent gravitropism cis. [Solution] cinnamic acid and/or cinnamic acid as an active ingredient to adjust gravitropism cis edge agents, cinnamic acid edge is, for example obtained by reacting compounds of the following formula. (In the formula, R is a phenyl group. )Figure 6 [drawing] (by machine translation)

Synthesis method of 8-aza coumarin and application thereof in antitumor drugs

The invention relates to a synthesis method of 8-aza coumarin. The synthesis method is implemented specifically in the following way: 3-substituted pyridine or quinolone nitrogen oxide is adopted as a raw material, acetic anhydride is adopted as a solvent and potassium carbonate is adopted as alkali; and in a condition of heating, 8-aza coumarin compounds are obtained through reactions. The method has the advantages of easiness in operation, cheap and easily available reagent, high reaction selectivity, wide primer applicability, high yield and the like. In the invention, a series of 8-aza coumarin compounds are obtained by the method for the first time, and the method has a broad prospect in establishing synthetic application of the compound library. Several 8-aza coumarin compounds synthesized are selected to test the in-vitro tumor cell inhibiting activity; and through experiments, the fact the 8-aza coumarin compounds have inhibiting activity on leukemia cells (K562) and hepatoma cells (HepG2) is found.

CIS CINNAMIC ACID ANALOG AND GRAVITROPISM MODIFIER

PROBLEM TO BE SOLVED: To provide a gravitropism modifier having effects on creeping property of plants or sugar content of fruits. SOLUTION: There is provided a gravitropism modifier containing cis cinnamic acid and/or a cinnamic acid analog represented by the formula (1) as active ingredients. (1), where A is cyclic hydrocarbon which may have a substituent, X is a bound or a C1 to 5 substituted or unsubstituted hydrocarbon chain, R1 is H, a hydroxyl group, an alkali earth metal salt or the like, R2 is a bond or a C1 to 5 substituted or unsubstituted hydrocarbon chain and R3 and R4 are H or together form C5 to 8 cyclic hydrocarbon. SELECTED DRAWING: Figure 6 COPYRIGHT: (C)2016,JPOandINPIT

From fragment screening to in vivo efficacy: Optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (bace1)

Using fragment-based screening of a focused fragment library, 2-aminoquinoline 1 was identified as an initial hit for BACE1. Further SAR development was supported by X-ray structures of BACE1 cocrystallized with various ligands and molecular modeling studies to expedite the discovery of potent compounds. These strategies enabled us to integrate the C-3 side chain on 2-aminoquinoline 1 extending deep into the P2′ binding pocket of BACE1 and enhancing the ligand's potency. We were able to improve the BACE1 potency to subnanomolar range, over 106-fold more potent than the initial hit (900 μM). Further elaboration of the physical properties of the lead compounds to those more consistent with good blood-brain barrier permeability led to inhibitors with greatly improved cellular activity and permeability. Compound 59 showed an IC50 value of 11 nM on BACE1 and cellular activity of 80 nM. This compound was advanced into rat pharmacokinetic and pharmacodynamic studies and demonstrated significant reduction of Aβ levels in cerebrospinal fluid (CSF).

Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase

The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endotheli

Preparation of quinoline-substituted carbonate and carbamate derivatives

The invention relates to a process for preparing quinoline-substituted carbonate and carbamate compounds, which are important intermediates in the synthesis of 6-O-substituted macrolide antibiotics. The process employs metal-catalyzed coupling reactions to provide a carbonate or carbamate of formula (I) or (II) or a substrate that can be reduced to obtain the same.